Carbon monoxide releasing molecule-2 increases the velocity of thrombus growth and strength in hemophilia A, hemophilia B and factor VII-deficient plasmas

Blood Coagulation and Fibrinolysis

Volumn 21, Issue 1, 2010, Pages 41-45

  Nielsen, Vance G ^a,b   Kirklin, James K ^b   George, James F ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

Carbon monoxide releasing molecule; Hemophilia; Thrombelastography

Indexed keywords

BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; CARBON MONOXIDE; RUTHENIUM DERIVATIVE; TRICARBONYLDICHLORORUTHENIUM; UNCLASSIFIED DRUG;

ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING FACTOR 7 DEFICIENCY; CONTROLLED STUDY; HEMOPHILIA A; HEMOPHILIA B; HUMAN; PRIORITY JOURNAL; STUDENT T TEST; THROMBOELASTOGRAPHY; THROMBOGENESIS;

BLOOD COAGULATION; CARBON MONOXIDE; DRUG EVALUATION, PRECLINICAL; FACTOR VII DEFICIENCY; HEMOPHILIA A; HEMOPHILIA B; HEMOSTATICS; HUMANS; ORGANOMETALLIC COMPOUNDS; PLASMA; PRODRUGS; THROMBELASTOGRAPHY; THROMBOPLASTIN;

EID: 75649137350     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e328331fd00     Document Type: Article

References (18)

1. Wu L, Wang R. Carbon monoxide: endogenous production, physiological functions, and pharmacological applications. Pharmacol Rev 2005; 57:585-630.
2. True AL, Olive M, Boehm M, San H, Westrick RJ, Raghavachari N, et al. Heme oxygenase-1 deficiency accelerates formation of arterial thrombosis through oxidative damage to the endothelium, which is rescued by inhaled carbon monoxide. Circ Res 2007; 101:893-901.
3. Motterlini R, Clark JE, Foresti R, Sarathchandra P, Mann BE, Green CJ. Carbon monoxide-releasing molecules: characterization of biochemical and vascular activities. Circ Res 2002; 90:e17-e24.
4. Motterlini R. Carbon monoxide-releasing molecules (CO-RMs): vasodilatory, antiischaemic and anti-inflammatory activities. Biochem Soc Trans 2007; 35:1142-1146.
5. Motterlini R, Mann BE, Foresti R. Therapeutic applications of carbon monoxide-releasing molecules. Expert Opin Investig Drugs 2005; 14:1305-1318.
6. Megias J, Busserolles J, Alcaraz MJ. The carbon monoxide-releasing molecule CORM-2 inhibits the inflammatory response induced by cytokines in Caco-2 cells. Br J Pharm 2007; 150:977-986.
7. Brune B, Ullrich V. Inhibition of platelet aggregation by carbon monoxide is mediated by activation of guanylate cyclase. Mol Pharmacol 1987; 32:497-504.
8. Brune B, Schmidt KU, Ullrich V. Activation of soluble guanylate cyclase by carbon monoxide and inhibition by superoxide anion. Eur J Biochem 1990; 192:683-688.
9. Chlopicki S, Olszanecki R, Marcinkiewicz E, Lomnicka M, Motterlini R. Carbon monoxide released by CORM-3 inhibits human platelets by a mechanism independent of soluble guanylate cyclase. Cardiovasc Res 2006; 71:393-401.
10. Nielsen VG, Kirklin JK, George JF. Carbon monoxide releasing molecule-2 (CORM-2) increases the velocity of thrombus growth and strength in human plasma. Blood Coagul Fibrinolysis 2009; 20:377-380.
11. Nielsen VG, Cohen BM, Cohen E. Effects of coagulation factor deficiency on plasma coagulation kinetics determined via Thrombelastography1: critical roles of fibrinogen and factors II, VII, X and XII. Acta Anaesthesiol Scand 2005; 49:222-231.
12. Nielsen VG, Cohen BM, Cohen E. Elastic modulus-based thrombelastographic quantification of plasma clot fibrinolysis with progressive plasminogen activation. Blood Coagul Fibrinolysis 2006; 17:75-81.
13. Johansen RF, Sorensen B, Ingerslev J. Acquired haemophilia: dynamic whole blood coagulation utilized to guide haemostatic therapy. Haemophilia 2006; 12:190-197.
14. Young G, Blain R, Nakagawa P, Nugent DJ. Individualization of bypassing agent treatment for haemophiliac patients with inhibitors utilizing thromboelastography. Haemophilia 2006; 12:598-604.
15. De Pietri L, Masetti M, Montalti R, Begliomini B, Reggiani B, Reggiani A, et al. Use of recombinant factor IX and throboelastography in a patient with hemophilia B undergoing liver transplantation: a case report. Transplant Proc 2008; 40:2007-2009.
16. Pivalizza EG, Escobar MA. Thrombelastography-guided factor VIIa therapy in a surgical patient with severe hemophilia and factor VIII inhibitor. Anesth Analg 2008; 107:398-401.
17. Young F, Ebbesen LS, Viuff D, Di Paola J, Konkle BA, Negrier C, et al. Evaluation of thromboelastography for monitoring recombinant activated factor VII ex vivo in haemophilia A and B patients with inhibitors: a multicentre trial. Blood Coagul Fibrinolysis 2008; 19:276-282.
18. Dehmel H, Werwitzke S, Trummer A, Ganser A, Tiede A. Thrombelastographic monitoring of recombinant factor VIIa in acquired haemophilia. Haemophilia 2008; 14:736-742.